Vizsgálati helyszín
OFTALMIKA Sp. z o.o
Bydgoszcz, 85-631, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis5 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Lezárult9 vizsgálat
- Toboroz7 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- Hoffmann-La Roche4 vizsgálat
- AbbVie3 vizsgálat
- Eyebiotech Limited2 vizsgálat
- EyeBiotech Ltd.2 vizsgálat
- EyePoint Pharmaceuticals, Inc.2 vizsgálat
- és még 14
Futó vizsgálatok
Toboroz
A Study in Adults With Geographic Atrophy
NCT07606365· 2. fázis· Sitala Bio LTD· Forrás
Toboroz
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
2025-524575-22-00· 2/3. fázis· Eyebiotech Limited· Forrás
Toboroz
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
NCT07614776· 3. fázis· Amgen· Forrás
Fut, nem toboroz
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523937-25-00· 3. fázis· Eyepoint Inc.· Forrás
Toboroz
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
2025-522231-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Toboroz
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225· 2/3. fázis· EyeBiotech Ltd.· Forrás
Contact: Study Coordinator
Toboroz
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Toboroz
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· 2/3. fázis· EyeBiotech Ltd.· Forrás
Fut, nem toboroz
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· 2/3. fázis· Eyebiotech Limited· Forrás
Toboroz
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· 3. fázis· Annexon, Inc.· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302· 2. fázis· Boehringer Ingelheim· Forrás
Meghívásos bevonás
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
NCT05481827· 2. fázis· Gyroscope Therapeutics Limited· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek